BCC’s newly released report, titled “Global Artificial Intelligence in Drug Discovery Market,” unveils the extraordinary …
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) and Seagen Inc. (Nasdaq: SGEN) …
MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil
MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective …
Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors
Today, Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- …
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to …
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, …
Crown Aesthetics Announces Launch Expansion of BIOJUVE™ Living Skin Biome Care into the United Kingdom, Ireland, and Germany
Crown Aesthetics (“Crown”), a division of Crown Laboratories, Inc., is excited to announce the launch …
RedHill Announces FDA sNDA Approval for Talicia®
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, announced the …
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines …
European Medicines Agency Validates Type II Variation for Astellas’ XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the …
